神经炎症
小胶质细胞
药物发现
表型筛选
表型
转基因小鼠
促炎细胞因子
阿尔茨海默病
神经退行性变
认知功能衰退
药理学
神经科学
淀粉样蛋白(真菌学)
生物
医学
转基因
疾病
炎症
生物信息学
免疫学
痴呆
病理
基因
遗传学
作者
Wei Zhou,Guifa Zhong,Sihai Fu,Hui Xie,Tianyan Chi,Luyi Li,Xiurong Rao,Shaogao Zeng,Dengfeng Xu,Hao Wang,Guoqing Sheng,Xing Ji,Xiaorong Liu,Xuefei Ji,Donghai Wu,Libo Zou,Micky Daniel Tortorella,Kejian Zhang,Wenhui Hu
标识
DOI:10.1021/acschemneuro.6b00125
摘要
Currently, anti-AD drug discovery using target-based approaches is extremely challenging due to unclear etiology of AD and absence of validated therapeutic protein targets. Neuronal death, regardless of causes, plays a key role in AD progression, and it is directly linked to neuroinflammation. Meanwhile, phenotypic screening is making a resurgence in drug discovery process as an alternative to target-focused approaches. Herein, we employed microglia-based phenotypic screenings to search for small molecules that modulate the release of detrimental proinflammatory cytokines. The identified novel pharmacological inhibitor of neuroinflammation (named GIBH-130) was validated to alter phenotypes of neuroinflammation in AD brains. Notably, this molecule exhibited comparable in vivo efficacy of cognitive impairment relief to donepezil and memantine respectively in both β amyloid-induced and APP/PS1 double transgenic Alzheimer's murine models at a substantially lower dose (0.25 mg/kg). Therefore, GIBH-130 constitutes a unique chemical probe for pathogenesis research and drug development of AD, and it also suggests microglia-based phenotypic screenings that target neuroinflammation as an effective and feasible strategy to identify novel anti-AD agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI